ARTICLE | Finance

Fulcrum’s genetic levers

Why Foresite led an $80M series B round for gene regulation play Fulcrum.

September 5, 2018 11:04 AM UTC

Fulcrum Therapeutics Inc.’s ability to identify targets for genetic disease drivers using bioinformatics prompted Foresite Capital to lead the company’s untranched $80 million series B round.

Fellow new investors Fidelity, 6 Dimensions Capital, Casdin Capital, Sanofi Ventures, Section 32, NS Investments, entities affiliated with Leerink Partners and undisclosed institutional investors also participated. ...